Article
Personalized medicine key to improving MIBC treatment
While neoadjuvant chemotherapy has been associated with a survival benefit in patients with muscle-invasive bladder cancer, patient selection needs to improve to optimize clinical outcomes and minimize costs, according to Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas.
While neoadjuvant chemotherapy has been associated with a survival benefit in patients with muscle-invasive bladder cancer, patient selection needs to improve to optimize clinical outcomes and minimize costs, according to Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas.
“There’s Level 1 evidence that neoadjuvant chemotherapy works [in patients with muscle-invasive disease],” Dr. Lotan said at the Genitourinary Cancers Symposium in San Francisco. But utilization is low and only one-fourth of unselected patients respond to treatment.
Personalized medicine may be the answer. In 3 to 5 years, new biomarkers will be validated and will help identify which patients will respond to neoadjuvant chemo, Dr. Lotan explains in this Urology Times video.
Dr. Lotan conducts scientific studies/trials for Abbott, Pacific Edge, FKD, Biocancell, GenomeDx Biosciences, Inc., MDxHealth, and Photocure; is a consultant/adviser to Cepheid and AstraZeneca; and has a leadership position with Vessi Medical.
